Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients (RECAD-AF)
|Atrial Fibrillation Coronary Artery Disease||Drug: Regadenoson MRI||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Detection of Coronary Artery Disease in Patients With Atrial Fibrillation Using Regadenoson Stress MRI|
- Sensitivity/specificity [ Time Frame: one MRI ]
All of the resting and stress scans of the subjects will be interpreted as positive or negative for CAD by two blinded expert readers.
Sensitivity/specificity will be calculated overall and subdivided into single vessel disease, two vessel, and three vessel disease. Confidence limits will also be calculated.
- Sensitivity/specificity image quality [ Time Frame: one MRI ]comparison of MRI image quality between subjects who were in normal sinus rhythm versus subjects who had an arrhythmia during the MRI
|Study Start Date:||January 2013|
|Study Completion Date:||October 2016|
|Primary Completion Date:||October 2016 (Final data collection date for primary outcome measure)|
Experimental: Regadenoson MRI
Participants with AF receiving regadenoson stress MRI
Drug: Regadenoson MRI
AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
Other Name: Lexiscan
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01710254
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84132|
|Principal Investigator:||Christopher J McGann, MD||University of Utah|